CASI Pharma Closes $10.3 Million Financing

CASI Pharma, a US-China biopharma, closed $10.3 million of a $25 million financing that was announced in September. The company will use the cash to speed up clinical trials of its lead cancer drug and in-license China rights to additional drug products. Previously, CASI disclosed the funding was led by a China investment fund manager affiliated with the same management team as the company's largest shareholder, IDG-Accel China Growth Fund III, L.P. More details.... Stock Symbol: (NSDQ: CASI) Share this with colleagues: // //